RESUMO
BACKGROUND: Cervical esophageal cancer (CEC) patients whose larynx function cannot be preserved often undergo chemoradiotherapy, whereas those with residual or recurrent lesions undergo a pharyngo-laryngo-esophagectomy (PLE); however, some need to undergo a pharyngolaryngectomy with total esophagectomy (PLTE) for synchronous or metachronous esophageal cancer. We retrospectively evaluated the relationship between preoperative irradiation (or the extent of esophageal resection) and postoperative endocrine complications in CEC, including hypothyroidism and hypoparathyroidism. METHODS: The cancers of 35 (5.4%) of 678 esophageal cancer patients with esophagectomy treated in 2000-2017 were CECs. We also analyzed the 17 cases of CEC patients who underwent PLE with thyroid lobectomy-11 with irradiation before PLE and 6 without irradiation. Seven patients underwent a PLTE. RESULTS: Hypothyroidism and hypoparathyroidism occurred in 14 and 12 patients, respectively. The hypothyroidism rate was significantly higher in patients with irradiation versus those without irradiation (100% vs. 50%; p = 0.010), and the hypoparathyroidism rate was significantly higher in the PLTE versus non-PLTE patients (100% vs. 50%; p = 0.026). The mean levothyroxine dosage was 1.60 µg/kg/day in the PLE patients post-irradiation. CONCLUSIONS: Irradiation appears to be a risk factor for hypothyroidism after PLE with thyroid lobectomy, while PLTE might have some effect on hypoparathyroidism. Due to vocal function loss, PLE patients may experience symptoms from endocrine complications. Levothyroxine treatment soon after PLE for post-irradiation patients and patients requiring as-needed calcium or vitamin D supplementation based on biochemical hypocalcemia for PLE (especially PLTE), may be effective in preventing symptomatic endocrine complications.
Assuntos
Neoplasias Esofágicas/cirurgia , Esofagectomia/métodos , Laringectomia/métodos , Glândulas Paratireoides/fisiopatologia , Faringectomia/métodos , Testes de Função Tireóidea , Idoso , Neoplasias Esofágicas/patologia , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos RetrospectivosRESUMO
Hypoparathyroidism is a disease characterized by inadequately low circulating concentrations of parathyroid hormone (PTH) resulting in low calcium levels and increased phosphate levels in the blood. Symptoms of the disease result from increased neuromuscular irritability caused by hypocalcaemia and include tingling, muscle cramps and seizures. The most common cause of the disease is inadvertent removal of, or injury to, the parathyroid glands during neck surgery, followed by genetic, idiopathic and autoimmune aetiologies. Conventional treatment includes activated vitamin D and/or calcium supplements, but this treatment does not fully replace the functions of PTH and can lead to short-term problems (such as hypocalcaemia, hypercalcaemia and increased urinary calcium excretion) and long-term complications (which include nephrocalcinosis, kidney stones and brain calcifications). PTH replacement has emerged as a new treatment option. Clinical trials using human PTH(1-34) and PTH(1-84) showed that this treatment was safe and effective in studies lasting up to 6 years. Recombinant human PTH(1-84) has been approved in the United States and Europe for the management of hypoparathyroidism; however, its effect on long-term complications is still being evaluated. Clinical practice guidelines, which describe the consensus of experts in the field, have been published and recognize the need for more research to optimize care. In this Primer, we summarize current knowledge of the prevalence, pathophysiology, clinical presentation and management of hypoparathyroidism.
Assuntos
Hiperfosfatemia/sangue , Hipocalcemia/sangue , Hipoparatireoidismo/diagnóstico , Hipoparatireoidismo/epidemiologia , Hormônio Paratireóideo/sangue , Adulto , Idoso , Cálcio/uso terapêutico , Europa (Continente)/epidemiologia , Feminino , Terapia de Reposição Hormonal/efeitos adversos , Humanos , Hipercalcemia/complicações , Hipoparatireoidismo/fisiopatologia , Hipoparatireoidismo/terapia , Masculino , Pessoa de Meia-Idade , Glândulas Paratireoides/fisiopatologia , Estados Unidos/epidemiologia , Vitamina D/uso terapêuticoRESUMO
BACKGROUND: Clinical and experiments evidence indicate that protease inhibitors (PI) can cause bone mineral density (BMD) loss. However, the mechanism of such loss remains obscure. METHODS: This single-center, cross-sectional study included 184 HIV-infected patients treated with PI who underwent dual-energy X-ray absorptiometry scan. Serum phosphorus, percentage of tubular reabsorption of phosphate (%TRP), thyroid and parathyroid function (iPTH), vitamin D, osteocalcin (OC), urinary deoxypyridinoline (DPD), and urinary cross-linked N-telopeptide of type I collagen (u-NTx) were measured. RESULTS: The rate of hypothyroidism in PI-users [32/117 (27%)] was double that in non-PI users [8/67 (12%), p = 0.016] and was significantly associated with PI use in multivariate analysis [odds ratio (OR) 11.37, 95% confidence interval (CI) 1.358-95.17, p = 0.025]. Spine BMD was significantly lower in hypothyroid patients than euthyroid, for both total population (-1.37 vs. -1.00, p = 0.041) and PI users (-1.56 vs. -1.13, p = 0.029). Multivariate regression analysis identified inverse correlation between hypothyroidism and spine BMD [estimate -0.437, 95% CI -0.858 to -0.024, p = 0.042]. OC, DPD and u-NTx were significantly higher in PI users than in non-PI users (p = 0.01, 0.05, and 0.01, respectively). CONCLUSIONS: PI use is associated with hypothyroidism as well as bone turnover acceleration, which worsens PI-associated BMD loss. In PI-treated patients, thyroid function tests are warranted to prevent further progression of PI-associated BMD loss.
Assuntos
Densidade Óssea/efeitos dos fármacos , Remodelação Óssea/efeitos dos fármacos , Hipotireoidismo/fisiopatologia , Inibidores de Proteases/farmacologia , Adolescente , Adulto , Aminoácidos/metabolismo , Colágeno Tipo I/metabolismo , Estudos Transversais , Humanos , Hipotireoidismo/sangue , Hipotireoidismo/metabolismo , Osteocalcina/metabolismo , Glândulas Paratireoides/fisiopatologia , Peptídeos/metabolismo , Fosfatos/metabolismo , Fósforo/sangue , Glândula Tireoide/fisiopatologia , Vitamina D/metabolismo , Adulto JovemRESUMO
BACKGROUND: Postoperative hypoparathyroidism is the most common complication after total thyroidectomy, owing to unintentional injury or decreased blood flow to the parathyroid glands. Prediction of postoperative hypoparathyroidism would be helpful for surgeons to manage postoperative hypocalcemia. In this study, we scored the discoloration of the parathyroid glands using a new parathyroid scoring system and evaluated the correlation between the parathyroid score and duration of required calcium supplementation after total thyroidectomy. METHODS: A total of 316 patients undergoing total thyroidectomy between November 2009 and April 2010 were enrolled in this retrospective study. Parathyroid scoring was performed by one experienced surgeon. The status of each of the 4 parathyroid glands was classified as normal color (3 points), slightly discolored (2 points), dark discoloration (1 point), or loss of the gland (0 points), resulting in possible total scores of 0-12. Serum parathyroid hormone (PTH), serum calcium, and ionized calcium concentrations were measured at 2 hours, 2 weeks, 3 months, 6 months, and 1 year after surgery. Patients were also divided into three groups based on the duration of required calcium supplementation: no required supplementation (n = 260, 82.3%), required supplementation for <6 months (n = 38, 12%), and required supplementation for ≥6 months (n = 18, 5.75%). RESULTS: Parathyroid scores were positively correlated with ionized PTH concentrations at 2 hours (r = 0.053, p < 0.001), 2 weeks (r = 0.056, p < 0.001), 3 months (r = 0.032, p<0.001), 6 months (r = 0.072, p < 0.001), and 1 year (r = 0.071, p < 0.001) after thyroidectomy. Parathyroid scores were significantly and inversely associated with the duration of required calcium supplementation (p = 0.001). CONCLUSIONS: Parathyroid scores at the end of surgery might be helpful for predicting the degree of postoperative hypocalcemia after total thyroidetomy.
Assuntos
Cálcio/sangue , Glândulas Paratireoides/cirurgia , Hormônio Paratireóideo/sangue , Tireoidectomia/métodos , Adulto , Idoso , Cálcio/administração & dosagem , Cor , Suplementos Nutricionais , Feminino , Humanos , Hipocalcemia/sangue , Hipocalcemia/diagnóstico , Hipocalcemia/tratamento farmacológico , Hipoparatireoidismo/sangue , Hipoparatireoidismo/diagnóstico , Masculino , Pessoa de Meia-Idade , Glândulas Paratireoides/irrigação sanguínea , Glândulas Paratireoides/fisiopatologia , Pigmentação , Complicações Pós-Operatórias/sangue , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/tratamento farmacológico , Período Pós-Operatório , Prognóstico , Estudos Retrospectivos , Sensibilidade e Especificidade , Tireoidectomia/efeitos adversos , Fatores de Tempo , Adulto JovemRESUMO
OBJECTIVE: To assess the correlation of serum parathyroid hormone (PTH) and vitamin D (25-OHD) levels based on different assays for measuring 25-OHD in healthy Saudi Arabians living along the east coast. PATIENTS AND METHODS: A cross-sectional study was conducted in 200 patients (150 women and 50 men aged between 18-69 years) between January 2011 and December 2012, attending outpatient clinic at King Fahd Hospital of the University, Al Khobar. The first 200 patients seen without vitamin D supplementation at clinic were enrolled in the study. Serum calcium, phosphorous, alkaline phosphatase, parathormone, and 25-OHD tests were performed. 25-OHD was assessed using:chemiluminescence immunoassay (CLIA)radioimmunoassay (RIA) using Wallac 1470 Gamma CounterHPLC -LC.MS (high performance liquid chromatography-liquid chromatography with mass spectrometry. The data was collected, entered into a database and analysed using SPSS, Inc., version 14. RESULTS: The mean age was 45.8±15.8 (18-74) years, and calcium level was 2.27±0.15 mmol/l. (range 2.125 to 2.62 mmol/l). Alkaline phosphatase was 88.91±35.94 (34-302) IU, parathormone 6.7±3.06 (1.35-21.2) (1.3-6.8 pmol/l). Of the participants, 188 were either vitamin D insufficient or deficient as measured by CLIA 11.85±6.14 (2-29.6), and 91 (48.4%) of them had secondary hyperparathyroidism 9.48±4.55 pc/l. Those with normal CLIA-measured 25-OHD levels had normal PTH levels. Of those with insufficiency, 4/21 (19%) had raised PTH levels; and of those with deficiency, 81/166 (48.79%) had raised levels, whereas with HPLC-LC.MS, 156 were shown to be insufficient and 97 deficient (with PTH level of 7.41±4.2). Thirteen of 41 patients (31.7%) with insufficiency were shown, by HPLC-LC.MS, to have raised PTH. All patients with vitamin D deficiency as diagnosed by HPLC-LC.MS had secondary hyperparathyroidism. CONCLUSIONS: The above results suggest that the method of measurement strongly influences vitamin D levels and that previous reports suggesting no association between vitamin D deficiency and secondary hyperparathyroidism should be viewed with caution.
Assuntos
Glândulas Paratireoides/fisiopatologia , Hormônio Paratireóideo/sangue , Deficiência de Vitamina D/fisiopatologia , Vitamina D/análogos & derivados , Adolescente , Adulto , Idoso , Fosfatase Alcalina/sangue , Cálcio/sangue , Estudos Transversais , Feminino , Voluntários Saudáveis , Humanos , Hiperparatireoidismo Secundário/sangue , Masculino , Pessoa de Meia-Idade , Vitamina D/sangue , Adulto JovemRESUMO
BACKGROUND: Aberrant mineral metabolism and bone diseases, which are commonly seen in chronic kidney disease (CKD), have been considered to be the important causes of morbidity and decreased quality of life. OBJECTIVES: We aimed to investigate the characteristics of calcium-phosphorus metabolism abnormalities and parathyroid dysfunction in elderly patients with chronic kidney disease undergoing hemodialysis. MATERIAL AND METHODS: A total of 336 patients undergoing maintenance hemodialysis were divided into two age groups: elderly (≥ 65 years) and non-elderly (< 65 years). Before dialysis, fasting blood samples were initially collected, then hemoglobin (Hb), serum creatinine (Scr), blood urea nitrogen (BUN), calcium, phosphorus, intact parathyroid hormone (iPTH), high-sensitivity C-reactive protein (HsCRP) and albumin (Alb) were measured. Serums BUN, ultrafiltration volume, dialysis duration and body weight were measured after dialysis. Finally, well-established formulas were used to obtain the serum albumin corrected calcium (Ac-Ca) and urea removal index (Kt/V). RESULTS: Elderly patients accounted for 52.7% of our patients; essential hypertension accounted for 35.6% of the cause for chronic renal failure, followed by chronic glomerulonephritis (21.5%) and diabetes mellitus (19.8%) in the elderly group; while in the non-elderly group, 43.4% of the chronic renal failure was due to chronic glomerulonephritis, followed by diabetes mellitus (23.9%) and essential hypertension (12.6%). Significant differences were found in the dialysis duration, blood pressure, concentrations of serum BUN, Scr, P, iPTH, Alb, standard-protein nitrogen present rate (nPNA) and Hs-CRP between the 2 groups. The multiple logistic regression analysis showed that age, plasma phosphorus, albumin and nPNA were independent risk factors for secondary hyperparathyroidism in patients undergoing maintenance hemodialysis. CONCLUSIONS: We conclude that most elderly patients undergoing hemodialysis experience hyperparathyroidism. The risk factors may include age and malnutrition but need further investigation.
Assuntos
Hiperparatireoidismo Secundário/etiologia , Glândulas Paratireoides/fisiopatologia , Diálise Renal , Insuficiência Renal Crônica/terapia , Fatores Etários , Idoso , Biomarcadores/sangue , Cálcio/sangue , Feminino , Humanos , Hiperparatireoidismo Secundário/sangue , Hiperparatireoidismo Secundário/diagnóstico , Hiperparatireoidismo Secundário/fisiopatologia , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Estado Nutricional , Glândulas Paratireoides/metabolismo , Hormônio Paratireóideo/sangue , Fósforo/sangue , Diálise Renal/efeitos adversos , Insuficiência Renal Crônica/sangue , Insuficiência Renal Crônica/complicações , Insuficiência Renal Crônica/diagnóstico , Fatores de Risco , Resultado do TratamentoRESUMO
Disturbances in mineral and bone metabolism are prevalent in chronic kidney disease (CKD) and are an important cause of morbidity, decreased quality of life Accordingly, instead of the classic term "Renal Osteodystrophy (ROD) " , a new term, "CKD-Mineral and Bone Disorders (CKD-MBD) " , has been proposed as a systemic disorder. In 2012, new Japanese Society for Dialysis Therapy (JSDT) clinical practice guideline for CKD-MBD is intended to assist the practitioner caring for adults and children with CKD stages 3-5, on HD therapy, on PD therapy or with a kidney transplant.
Assuntos
Distúrbio Mineral e Ósseo na Doença Renal Crônica/terapia , Diálise , Nefropatias/terapia , Guias de Prática Clínica como Assunto , Sociedades Médicas , Adulto , Osso e Ossos/metabolismo , Cálcio/sangue , Criança , Doença Crônica , Distúrbio Mineral e Ósseo na Doença Renal Crônica/sangue , Distúrbio Mineral e Ósseo na Doença Renal Crônica/etiologia , Distúrbio Mineral e Ósseo na Doença Renal Crônica/metabolismo , Distúrbio Mineral e Ósseo na Doença Renal Crônica/fisiopatologia , Diálise/efeitos adversos , Humanos , Japão , Nefropatias/complicações , Nefropatias/metabolismo , Nefropatias/fisiopatologia , Glândulas Paratireoides/fisiopatologia , Fósforo/sangueRESUMO
Phosphate homeostasis in humans is a complex phenomenon involving the interplay of several different organs and circulating hormones. Among the latter, parathyroid hormone (PTh), and vitamin D3 (Vit D3) were thought to be the main regulators of serum phosphate concentration since they mediated the intestinal, renal and bone responses that follow fluctuations in serum phosphate levels. The study of three rare disorders - tumor-induced osteomalacia (TIo), autosomal dominant hypophosphatemic rickets (ADhr) and X-linked hypophosphatemic rickets (XLh) - has offered a completely new insight into phosphate metabolism by unraveling the role of a group of peptides that can directly affect serum phosphate concentration by increasing urinary phosphate excretion. fibroblast growth factor-23 (fGf-23) is the most extensively studied ''phosphatonin''. The production, mechanism of action, effects in various target tissues, and its role in common clinical disorders are the focus of this review.
Assuntos
Fatores de Crescimento de Fibroblastos/fisiologia , Rim/fisiologia , Fósforo/fisiologia , Animais , Doença Crônica , Fator de Crescimento de Fibroblastos 23 , Fatores de Crescimento de Fibroblastos/metabolismo , Taxa de Filtração Glomerular/fisiologia , Homeostase/fisiologia , Humanos , Hipofosfatemia/fisiopatologia , Absorção Intestinal/fisiologia , Nefropatias/fisiopatologia , Nefrolitíase/fisiopatologia , Glândulas Paratireoides/fisiopatologia , Fosfatos/metabolismo , Fosfatos/fisiologiaRESUMO
OBJECTIVE: The study aimed to investigate the effect of high dose radioactive iodine (RAI) on parathyroid function in patients with differentiated thyroid cancer. METHODS: Nineteen patients (8 men/11 women, age 46.5 +/- 13.2 years) undergoing RAI for thyroid remnant ablation were enrolled in the study. The biochemical parameters related to parathyroid function [serum calcium (Ca), phosphate (P), creatinine (Cr), alkaline phosphatase (ALP), intact parathyroid hormone (iPTH), urinary Ca, cAMP concentrations and the maximum tubular capacity for phosphate per unit volume of glomerular filtrate (TmP/GFR)] were evaluated at baseline and at the 1st, 3rd, 6th and 12th months of RAI administration. SPSS 15.0 was used for statistical analysis. RESULTS: For all patients, thyroid-stimulating hormone levels were >30 U/ml at baseline and <0.1 U/ml at the following visits. Serum iPTH levels were decreased significantly at the 6th month and reached basal levels at the 12th month (baseline vs. 6th p = 0.027, 1st vs. 6th p = 0.011, 3rd vs. 6th p = 0.047, 3rd vs. 12th p = 0.014, 6th vs. 12th p = 0.001). At the 6th month, P and TmP/GFR levels were higher (p = 0.036, 0.017, respectively), and urinary cAMP measurements were lower (p = 0.020) compared to those of the 1st month. No difference was detected concerning the other parameters. Serum Ca levels decreased below 2.1 mmol/l in several patients (n = 5 at 1st month, n = 4 at 3rd month, n = 8 at 6th month and n = 3 at 12th month) without clinical symptoms. CONCLUSIONS: The study indicated a transient decline in PTH levels at the 6th month following RAI therapy. Although this decrease did not cause symptoms in any of the present cases, this pattern might be important especially in individuals with diminished parathyroid background.
Assuntos
Radioisótopos do Iodo/administração & dosagem , Radioisótopos do Iodo/efeitos adversos , Glândulas Paratireoides/fisiopatologia , Glândulas Paratireoides/efeitos da radiação , Doses de Radiação , Radioterapia/efeitos adversos , Neoplasias da Glândula Tireoide/radioterapia , Cálcio/sangue , Feminino , Humanos , Radioisótopos do Iodo/uso terapêutico , Masculino , Pessoa de Meia-Idade , Glândulas Paratireoides/metabolismo , Hormônio Paratireóideo/sangue , Dosagem Radioterapêutica , Neoplasias da Glândula Tireoide/sangue , Fatores de TempoRESUMO
The mechanism of regulation of Parathyroid hormone (PTH) is complex, and diverse factors are involved: the fundamental ones are calcium, calcitriol and phosphorus. Calcium and calcitriol's mechanism of action takes place through its specific receptors, the calcium-sensing receptor (CaR) and the Vitamin D Receptor (VDR). These two factors have an effect not only on its specific receptors, but also they can modify the other receptor in a positive manner, promoting its actions and demonstrating a cooperative effect between the two. Along with calcium and calcitriol, drugs used in the treatment of Chronic Kidney Disease Mineral Bone Disorders (CKD-MBD) also act directly or indirectly on CaR and VDR and therefore are also responsible for the regulation of the parathyroid gland.
Assuntos
Calcitriol/fisiologia , Cálcio/fisiologia , Glândulas Paratireoides/fisiologia , Receptores de Calcitriol/fisiologia , Receptores de Detecção de Cálcio/fisiologia , Alumínio/farmacologia , Alumínio/fisiologia , Animais , Calcitriol/farmacologia , Regulação da Expressão Gênica/efeitos dos fármacos , Regulação da Expressão Gênica/fisiologia , Homeostase , Humanos , Hipercalcemia/fisiopatologia , Hiperparatireoidismo/fisiopatologia , Hipocalcemia/fisiopatologia , Falência Renal Crônica/fisiopatologia , Técnicas de Cultura de Órgãos , Glândulas Paratireoides/fisiopatologia , Hormônio Paratireóideo/fisiologia , Fósforo/farmacologia , Fósforo/fisiologia , Ratos , Transdução de Sinais/fisiologiaRESUMO
BACKGROUND: Transient hypocalcemia is one of the postoperative complications of thyroidectomy for Graves' disease, and perioperative parathyroid hormone (PTH) assays are used to predict postoperative hypocalcemia. We evaluated long-term changes in parathyroid function after surgery for Graves' disease. METHODS: Serum PTH values were measured in Graves' patients with postoperative hypocalcemia, and those patients were followed postoperatively. RESULTS: Subtotal thyroidectomy was performed in 275 patients with Graves' disease. Their serum calcium levels were measured on postoperative day (POD) 1, and patients with transient postoperative hypocalcemia were treated with calcium and vitamin D supplementation and followed up. The amount of calcium and vitamin D supplementation was adjusted to keep the patient's serum calcium level within the normal range. Measurement of their serum intact PTH value on POD 1 revealed normal value in 18 patients, a below normal level in 22, and an above normal level in the other 2. During the follow-up period, the serum iPTH values remained normal in 12 patients, recovered to the normal level in 21 patients, and rose above the normal range in 9 patients. The serum iPTH values of all patients eventually reached the normal range during the follow-up period. A marked difference in preoperative serum alkaline phosphatase concentration was observed between the high-iPTH patients and the normocalcemic patients. CONCLUSIONS: The phenomenon of an elevated serum PTH level after surgery for Graves' disease was observed in 21% of the patients with postoperative hypocalcemia despite the achievement of normal serum calcium levels by calcium and vitamin D supplementation.
Assuntos
Doença de Graves/sangue , Doença de Graves/cirurgia , Hipocalcemia/sangue , Glândulas Paratireoides/fisiopatologia , Hormônio Paratireóideo/sangue , Tireoidectomia/efeitos adversos , Adolescente , Adulto , Feminino , Seguimentos , Humanos , Hipocalcemia/etiologia , Hipocalcemia/terapia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
INTRODUCTION: Transient and persistent hypoparathyroidism (HPT) belong to the well known complications of total thyroidectomy performed because of thyroid carcinoma. The true frequency of persistent hypoparathyroidism is often higher than estimated in the reports published by the specialized centers with low rate of complications. THE AIM OF THE STUDY: Investigation whether the repeated check-up, performed over 2 years post thyroidectomy, reveals some cases of recovery in patients diagnosed with persistent HPT post thyroid cancer surgery. MATERIAL AND METHODS: In total, 115 patients were included into the study, all of them treated with vitamin D derivatives and calcium supplementation. In 17 of them a diagnosis of transient hypoparathyroidism was made on the basis of evaluation performed 6 months after surgery, the remaining 98 were diagnosed with persistent HPT. Parathyroid (PTH) function was reevaluated after withdrawal of active vitamin D derivatives for 10 days and of calcium carbonate for two days during the hospital stay in patients admitted for radioiodine scan, thus after thyroxine withdrawal. The control group consisted of 123 DTC (differentiated thyroid carcinoma) patients without parathyroid dysfunction. On the basis of intact PTH serum level and calcium and phosphorus estimations HPT was unequivocally confirmed in 49 patients (50%). The remaining 49 patients exhibited normal PTH level and in 43 (86%) of them Ca(2+) level was also within normal range, thus delayed, recovery from HPT was stated. RESULTS: Our results indicate that reevaluation of hypoparathyroidism post total thyreoidectomy is necessary, as delayed recover of parathyroid dysfunction is a frequent phenomenon. We also propose criteria of reevaluation of HTP in patients on chronic substitutive therapy.
Assuntos
Hipoparatireoidismo/tratamento farmacológico , Hipoparatireoidismo/etiologia , Complicações Pós-Operatórias/tratamento farmacológico , Neoplasias da Glândula Tireoide/cirurgia , Tireoidectomia/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Cálcio/sangue , Cálcio/uso terapêutico , Suplementos Nutricionais , Feminino , Seguimentos , Humanos , Hipocalcemia/sangue , Hipocalcemia/tratamento farmacológico , Hipocalcemia/etiologia , Hipoparatireoidismo/metabolismo , Masculino , Pessoa de Meia-Idade , Glândulas Paratireoides/fisiopatologia , Glândulas Paratireoides/cirurgia , Recuperação de Função Fisiológica , Estudos Retrospectivos , Neoplasias da Glândula Tireoide/patologia , Resultado do Tratamento , Vitamina D/uso terapêuticoRESUMO
BACKGROUND: The functional results of cryopreserved heterotopic parathyroid autotransplantation (CHPA) are not well defined. The authors evaluated the outcomes of delayed CHPA for the treatment of surgically induced hypoparathyroidism. METHODS: Since November 1991, 448 parathyroid samples from 436 patients were cryopreserved at our institution. Of these, 29 patients underwent 34 CHPA procedures, with placement of 20 to 25 pieces of parathyroid tissue (approximately 50 to 75 mg) into the forearm. Outcomes were determined based on peripheral parathyroid hormone (PTH) levels and, where available, PTH gradients between grafted and nongrafted arms. Graft function results were defined as completely functional (patients with normal PTH and calcium levels off all calcium/vitamin D supplementation), partially functional (normal PTH levels and mild hypocalcemia on calcium supplementation), or nonfunctional (low PTH levels and dependent on calcium/vitamin D supplementation). RESULTS: Of the 29 patients with CHPA, prospective data were available for 26 patients undergoing 30 CHPA procedures (9 patients with MEN 1, 4 with MEN 2A, 1 with MEN 2B, and 12 with sporadic hyperparathyroidism). The mean follow-up interval was 2 years. Twelve of 26 patients (46%) had completely functional grafts, 6 patients (23%) had partially functional grafts, and the remaining 8 patients (31%) had nonfunctional grafts. No patient with CHPA had graft-dependent recurrent hyperparathyroidism. Of the 14 patients (15 autografts) with MEN, 7 patients (50%) had fully functional grafts, and 2 patients (14%) had partially functional grafts. The mean cryopreservation period was 7.9 months (range, 1 week to 22 months) for functional autografts and 15.3 months (range, 2 weeks to 106 months) for nonfunctional autografts (P < .01). CONCLUSIONS: Based on these data and those in previous studies, approximately 60% of delayed, cryopreserved parathyroid autografts are functional. In this study 40% autografts (46% of patients) achieved full competency off supplements. Some patients have evidence of graft function with normal PTH levels but are not normocalcemic. Results were similar for patients with MEN and nonhereditary hyperparathyroidism. The duration of cryopreservation was a significant indicator of graft failure, and no functional autograft was observed beyond 22 months of preservation. CHPA is a useful treatment modality for patients with postoperative hypocalcemia after thyroid or parathyroid surgery, who do not respond to immediate parathyroid autotransplantation.
Assuntos
Criopreservação , Hipoparatireoidismo/cirurgia , Glândulas Paratireoides/fisiopatologia , Glândulas Paratireoides/transplante , Recuperação de Função Fisiológica/fisiologia , Transplante Heterotópico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Feminino , Seguimentos , Humanos , Hipoparatireoidismo/sangue , Masculino , Pessoa de Meia-Idade , Músculo Esquelético , Hormônio Paratireóideo/sangue , Estudos Prospectivos , Fatores de Tempo , Resultado do TratamentoRESUMO
Secondary hyperparathyroidism (SHPT) is one of the serious complications in patients with chronic kidney disease. Parathyroid glands secrete parathyroid hormone (PTH), stimulated partly by hyperphosphatemia and hypocalcemia complicating chronic kidney disease (CKD). Use of a calcium-based phosphate binder might be sufficient to reduce serum PTH levels in mild SHPT, while the recent K/DOQI clinical guidelines recommended vitamin D therapy for dialysis patients with serum level of intact parathyroid hormone of 300 pg/mL or more. We conducted a 6-month prospective controlled trial of 50 patients initiating hemodialysis therapy who were randomized to receive oral calcium carbonate alone or the drug plus oral vitamin D sterol, calcitriol or alfacalcidol. The primary end point was the proportion of randomized patients who had a mean PTH level of 300 pg/mL or less at the end of this study. The secondary end point included the percent change in the values for corrected calcium, phosphorus, the calcium-phosphorus product, and PTH. Eighty percent of patients receiving calcium carbonate without vitamin D sterols (20 of 25) reached the primary end point-a mean PTH level of 300 pg/mL or less after the period-as compared with 84% of those receiving calcium carbonate and vitamin D sterol (21 of 25) (Mantel-Haenszel odds ratio 0.76, 95% confidence interval: 0.18-3.25, P = 0.71). The other effects of the two regimens on the secondary end points were not significantly different after 6 months. In SHPT of dialysis patients initiating hemodialysis, oral calcium carbonate use alone was not inferior to additional vitamin D sterol use with calcium carbonate in reducing serum PTH levels. Our result indicated that, if serum calcium and phosphorus levels are controlled primarily regardless of used agents, it will be followed by reduction of serum PTH level in these patients.
Assuntos
Hiperparatireoidismo Secundário/prevenção & controle , Falência Renal Crônica/fisiopatologia , Glândulas Paratireoides/fisiopatologia , Hormônio Paratireóideo/sangue , Diálise Renal , Administração Oral , Calcitriol/administração & dosagem , Calcitriol/uso terapêutico , Cálcio/sangue , Carbonato de Cálcio/administração & dosagem , Carbonato de Cálcio/uso terapêutico , Feminino , Seguimentos , Humanos , Hidroxicolecalciferóis/administração & dosagem , Hidroxicolecalciferóis/uso terapêutico , Hiperparatireoidismo Secundário/tratamento farmacológico , Falência Renal Crônica/terapia , Masculino , Pessoa de Meia-Idade , Fósforo/sangue , Estudos Prospectivos , Fatores de TempoAssuntos
Adenocarcinoma Folicular/radioterapia , Carcinoma Papilar/radioterapia , Radioisótopos do Iodo/administração & dosagem , Neoplasias da Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/radioterapia , Adenocarcinoma Folicular/secundário , Adolescente , Adulto , Idoso , Neoplasias Ósseas/secundário , Carcinoma Papilar/secundário , Criança , Aberrações Cromossômicas/efeitos da radiação , Relação Dose-Resposta à Radiação , Humanos , Hipoparatireoidismo/etiologia , Pulmão/fisiopatologia , Neoplasias Pulmonares/secundário , Metástase Linfática , Pessoa de Meia-Idade , Glândulas Paratireoides/fisiopatologia , Glândulas Salivares/fisiopatologia , Neoplasias da Glândula Tireoide/genéticaRESUMO
The role of the double phase parathyroid scintigraphy with MIBI in the primary hyperparathyroidism has been well studied. The present work analyzes the benefit of this image technique in the diagnosis and therapeutic approach to uremia associated hyperparathyroidism. We studied 18 dialysis patients with clinical and analytical data of hyperparathyroidism. All of them were receiving treatment with i.v. vitamin D. We carried out two scintigraphic studies, the first under basal conditions (without changes in treatment) and the second one, a week later after the stimulation of the parathyroid gland through the cessation of the treatment with vitamin D and phosphorus binders, and the use of a low-calcium dialysate. In the basal study, fourteen patients had a positive uptake test in at least one of the four glands. These patients had significantly higher PTHi levels than those with a negative scintigraphic study. After the stimulation test, we found a statistically significative rise in PHTi (644 vs 979 p < 0.001) and phosphorus levels (5.8 vs 7.3; p < 0.01), a slight fall in calcium levels (p = NS) and a statistically significative increment in the score of scintigraphic captation (5.5 +/- 4.5 vs 6.8 +/- 5; p < 0.05). We found a statistically significative correlation between the PTHi level and the score of scintigraphic uptake, in the basal study (r = 0.6, p < 0.01) and after stimulation (r = 0.6, p < 0.01). The only variable associated with the scintigraphic uptake was PTHi, justifying 31.1% of the variance in the first study and 32.7% in the second. In conclusion, the MIBI scintigraphic is a useful exploration in the uremic patient with hyperparathyroidism, as it predicts the functional state of the parathyroid glands according to uptake intensity. The stimulation test could be useful in planning therapy, but some of its characteristics need to be established, such as the precise time to reach the maximum level of parathyroid stimulation.
Assuntos
Hiperparatireoidismo Secundário/diagnóstico por imagem , Glândulas Paratireoides/diagnóstico por imagem , Compostos Radiofarmacêuticos , Tecnécio Tc 99m Sestamibi , Uremia/complicações , Acetatos/administração & dosagem , Acetatos/uso terapêutico , Adulto , Idoso , Calcitriol/administração & dosagem , Calcitriol/uso terapêutico , Cálcio/sangue , Carbonato de Cálcio/administração & dosagem , Carbonato de Cálcio/uso terapêutico , Compostos de Cálcio , Feminino , Humanos , Hiperparatireoidismo Secundário/tratamento farmacológico , Hiperparatireoidismo Secundário/metabolismo , Hiperparatireoidismo Secundário/fisiopatologia , Masculino , Pessoa de Meia-Idade , Glândulas Paratireoides/fisiopatologia , Hormônio Paratireóideo/sangue , Hormônio Paratireóideo/metabolismo , Fósforo/sangue , Cintilografia , Compostos Radiofarmacêuticos/farmacocinética , Diálise Renal , Taxa Secretória , Tecnécio Tc 99m Sestamibi/farmacocinética , Uremia/metabolismo , Uremia/fisiopatologia , Uremia/terapiaRESUMO
Rabbits with renal failure have been reported to be hypercalcemic and to have decreased parathyroid hormone (PTH) concentrations. Thus, it would seem that uremic rabbits are resistant to secondary hyperparathyroidism (HPT). The work reported here was designed to investigate parathyroid gland function in uremic rabbits and the effect of diets with different calcium (Ca) and phosphorus (P) content. The relationship between PTH and ionized calcium (Ca2+), parathyroid gland size and parathyroid cell cycle were studied in three groups of rabbits: Group I, rabbits with normal renal function on a standard diet (Ca = 1.2%, P = 0.6%); Group II, partially nephrectomized rabbits on a standard diet; and Group III, partially nephrectomized rabbits on a low Ca (0.6%)-high P (1.2%) diet. Group I rabbits had baseline Ca2+ = 1.71 +/- 0.05 mmol/l and PTH = 26.9 +/- 3.2 pg/ml. During hypo- and hypercalcemic stimulation PTH reached maximal values (PTHmax) of 94.4 +/- 5.5 pg/ml and minimal concentrations (PTHmin) of 3.2 +/- 0.2 pg/ml. Rabbits from Group II were hypercalcemic (baseline Ca2+ = 2.03 +/- 0.06 mmol/l) and had very low PTH levels (1.7 +/- 0.5 pg/ml); however, they reached a PTHmax that was similar to Group I, 92 +/- 8.7 pg/ml. Group III rabbits were hypocalcemic (baseline Ca2+ = 1.22 +/- 0.08 mmol/l) and had very high basal PTH levels (739 +/- 155 pg/ml). Their PTHmax and PTHmin were 801 +/- 169.4 pg/ml and 102.2 +/- 22.2 pg/ml, respectively. Both parathyroid gland size and parathyroid cell proliferation were increased in Group III. In conclusion, our results show that the Ca and P content of the diet markedly influence PTH secretion in the uremic rabbit and that when placed on a low Ca-high P diet uremic rabbits develop secondary HPT.
Assuntos
Cálcio/sangue , Glândulas Paratireoides/fisiopatologia , Hormônio Paratireóideo/metabolismo , Fósforo/sangue , Coelhos , Insuficiência Renal/veterinária , Uremia/veterinária , Análise de Variância , Ração Animal , Animais , Cálcio da Dieta/sangue , Feminino , Hipercalcemia/sangue , Hipercalcemia/veterinária , Hipocalcemia/sangue , Hipocalcemia/veterinária , Masculino , Nefrectomia/veterinária , Hormônio Paratireóideo/sangue , Insuficiência Renal/fisiopatologia , Uremia/fisiopatologiaRESUMO
The parathyroid glands have a great sensitivity to small changes in the extracellular ionic calcium. The calcium-sensing receptor (CaR) is a G protein-coupled receptor that responds to extracellular ionic calcium changes activating several intracellular signalling systems (phospholipases C, A2 and D) finally inhibiting the PTH secretion. In addition to calcium, there are some other agonists and modulators such as the Mg2+, spermine, amyloid beta-peptides, a variety of aminoacids, especially aromatic aminoacids and ionic strength. In the uraemia, the sensitivity of the parathyroid glands to calcium is altered and higher values of calcium are necessary to suppress the PTH. In the secondary hyperparathyroidism the CaR expression is reduced. It has been found a negative correlation between cellular proliferation and the expression of the CaR in hyperplasic glands. Despite it is a calcium receptor, the expression of the CaR does not seem to be regulated by calcium and there is some controversy about the role of calcitriol regulating its expression. On the other hand, the phosphorous induces hyperplasia of the parathyroid gland increasing the cellular proliferation and a decrease of the CaR expression.
Assuntos
Cálcio/fisiologia , Hiperparatireoidismo Secundário/fisiopatologia , Falência Renal Crônica/complicações , Glândulas Paratireoides/fisiopatologia , Hormônio Paratireóideo/fisiologia , Receptores de Superfície Celular/fisiologia , Aminoácidos/fisiologia , Peptídeos beta-Amiloides/fisiologia , Animais , Calcitriol/fisiologia , Cálcio/sangue , Sinalização do Cálcio , Humanos , Hipocalcemia/etiologia , Falência Renal Crônica/fisiopatologia , Magnésio/fisiologia , Concentração Osmolar , Fósforo/fisiologia , Ratos , Receptores de Detecção de Cálcio , Transdução de Sinais , Espermina/fisiologiaRESUMO
Las glándulas paratiroides tienen una gran sensibilidad a pequeños cambios en el calcio iónico extracelular. El receptor sensor de calcio (CaR) es un receptor acoplado a proteínas G que es capaz de responder a incrementos en el calcio extracelular activando una serie de señales intracelulares (fosfolipasas C, A2 y D) y cuyo resultado final es la inhibición de la secreción de PTH. Además del calcio, existen otros agonistas y moduladores del CaR como el Mg, espermina, péptidos amilodes β, ciertos aminoácidos, especialmente los aminoácidos aromáticos y la fuerza iónica. En la uremia la sensibilidad de las glándulas paratiroides al calcio está alterada, necesitando concentraciones más altas del mismo para suprimir la PTH. En el hiperparatiroidismo secundario la expresión del CaR se encuentra reducida. En glándulas hiperplásicas se ha observado una correlación negativa entre la proliferación celular y la expresión del CaR. A pesar de ser un receptor de calcio, la expresión del CaR no parece estar regulada por el calcio y existe una cierta discrepancia sobre si el calcitriol es capaz de regular su expresión. Por otro lado, el fósforo provoca una hiperplasia de la glándula paratiroides incrementando la proliferación celular y un descenso en la expresión del CaR (AU)
The parathyroid glands have a great sensitivity to small changes in the extracellular ionic calcium. The calcium-sensing receptor (CaR) is a G protein-coupled receptor that responds to extracellular ionic calcium changes activating several intracellular signaling systems (phospholipases C, A2 and D) finally inhibiting the PTH secretion. In addition to calcium, there are some other agonists and modulators such as the Mg2+, spermine, amyloid β-peptides, a variety of aminoacids, especially aromatic aminoacids and ionic strength. In the uraemia, the sensitivity of the parathyroid glands to calcium is altered and higher values of calcium are necessary to suppress the PTH. In the secondary hyperparathyroidism the CaR expression is reduced. It has been found a negative correlation between cellular proliferation and the expression of the CaR in hyperplasic glands. Despite it is a calcium receptor, the expression of the CaR does not seem to be regulated by calcium and there is some controversy about the role of calcitriol regulating its expression. On the other hand, the phosphorous induces hyperplasia of the parathyroid gland increasing the cellular proliferation and a decrease of the CaR expression (AU)